Home > Insider Trading > Filing (0001209191-19-034851)

Filing Details

Accession Number:: 0001209191-19-034851
Form Type:: 4
Zero Holdings:: No
Publication Time:: 2019-06-05 17:41:11
Reporting Period:: 2019-06-03

Accepted Time:: 2019-06-05 17:41:11
SEC Url:: Form 4 Filing

Issuer

Cik	Name	Symbol	Sector (SIC)	IRS No
1717452	Odonate Therapeutics Inc.	ODT	()	4

Insiders

Cik	Name	Reported Address	Insider Title	Director	Officer	Large Shareholder	Other
1178579	C Kevin Tang	4747 Executive Drive Suite 510 San Diego CA 92121	Chief Executive Officer	Yes	Yes	Yes	No
1191935	Tang Capital Partners Lp	4747 Executive Drive Suite 510 San Diego CA 92121		No	No	Yes	No
1232621	Tang Capital Management Llc	4747 Executive Drive Suite 510 San Diego CA 92121		No	No	Yes	No
1495904	G John Lemkey	4747 Executive Drive Suite 510 San Diego CA 92121	Chief Operating Officer	No	Yes	No	No
1759910	S Michael Hearne	4747 Executive Drive Suite 510 San Diego CA 92121	Chief Financial Officer	No	Yes	No	No

Reported Non-Derivative Transactions

Show Other Fields >>

Sec. Name	Acquisiton - Disposition	Date	Amount	Price	Remaning Holdings	Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
Common Stock	Acquisiton	2019-06-03	7,859	$22.16	13,093,897	No	4	P	Indirect	By LP
Common Stock	Acquisiton	2019-06-03	7,427	$22.86	13,101,324	No	4	P	Indirect	By LP
Common Stock	Acquisiton	2019-06-04	34,714	$24.92	13,136,038	No	4	P	Indirect	By LP
Common Stock	Acquisiton	2019-06-04	4,236	$24.99	13,140,274	No	4	P	Indirect	By LP
Common Stock	Acquisiton	2019-06-05	9,972	$25.14	13,150,246	No	4	P	Indirect	By LP
Common Stock	Acquisiton	2019-06-05	29,484	$26.11	13,179,730	No	4	P	Indirect	By LP

Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
No	4	P	Indirect	By LP
No	4	P	Indirect	By LP
No	4	P	Indirect	By LP
No	4	P	Indirect	By LP
No	4	P	Indirect	By LP
No	4	P	Indirect	By LP

Footnotes

The prices reported in Column 4 are weighted-average prices. These shares were purchased in multiple transactions at prices ranging from $21.48 to $22.47. The Reporting Persons undertake to provide the Issuer, any security holder of the Issuer or the SEC Staff, upon request, full information regarding the number of shares purchased at each price within the ranges set forth in footnotes 1 and 3 through 7 herein.
The securities are beneficially owned by Tang Capital Partners, LP ("TCP"). Kevin Tang is the sole manager of Tang Capital Management,LLC ("TCM"), which is the general partner of TCP. The shares reported as beneficially owned by TCP include a total of 154,285 shares ofcommon stock that are held of record by Odonate Holdings, LLC ("Holdings"). Holdings has granted a proxy to TCP giving TCP the sole authorityto vote such shares. John Lemkey is the Chief Operating Officer of Odonate Therapeutics, Inc., as well as Chief Operating Officer of TCM. Michael Hearne is the Chief Financial Officer of Odonate Therapeutics, Inc., as well as Chief Financial Officer of TCM. Mr. Tang, Mr. Lemkey and Mr. Hearne each have a pecuniary interest in a portion of the shares beneficially held by TCP.
The prices reported in Column 4 are weighted-average prices. These shares were purchased in multiple transactions at prices ranging from $22.48 to $23.00.
The prices reported in Column 4 are weighted-average prices. These shares were purchased in multiple transactions at prices ranging from $24.41 to $25.00.
The prices reported in Column 4 are weighted-average prices. These shares were purchased in multiple transactions at prices ranging from $24.91 to $25.00.
The prices reported in Column 4 are weighted-average prices. These shares were purchased in multiple transactions at prices ranging from $24.76 to $25.75.
The prices reported in Column 4 are weighted-average prices. These shares were purchased in multiple transactions at prices ranging from $25.76 to $26.50.